Mersana Therapeutics, Inc. (MRSN): Price and Financial Metrics

Mersana Therapeutics, Inc. (MRSN): $3.78

0.09 (+2.44%)

POWR Rating

Component Grades

Momentum

D

Stability

F

Sentiment

Quality

C

Add MRSN to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#293 of 356

in industry

MRSN Price/Volume Stats

Current price $3.78 52-week high $9.62
Prev. close $3.69 52-week low $0.80
Day low $3.63 Volume 1,479,900
Day high $3.88 Avg. volume 2,042,875
50-day MA $2.91 Dividend yield N/A
200-day MA $2.96 Market Cap 456.29M

MRSN Stock Price Chart Interactive Chart >

MRSN POWR Grades

  • MRSN scores best on the Growth dimension, with a Growth rank ahead of 68.83% of US stocks.
  • The strongest trend for MRSN is in Quality, which has been heading up over the past 26 weeks.
  • MRSN ranks lowest in Stability; there it ranks in the 3rd percentile.

MRSN Stock Summary

  • Revenue growth over the past 12 months for MERSANA THERAPEUTICS INC comes in at 243.1%, a number that bests 97.82% of the US stocks we're tracking.
  • The volatility of MERSANA THERAPEUTICS INC's share price is greater than that of 97.02% US stocks with at least 200 days of trading history.
  • MERSANA THERAPEUTICS INC's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -52.23%, greater than the shareholder yield of just 7.75% of stocks in our set.
  • Stocks that are quantitatively similar to MRSN, based on their financial statements, market capitalization, and price volatility, are TSVT, CRDF, IPSC, VYGR, and HYLN.
  • Visit MRSN's SEC page to see the company's official filings. To visit the company's web site, go to www.mersana.com.

MRSN Valuation Summary

  • In comparison to the median Healthcare stock, MRSN's price/sales ratio is 64.29% higher, now standing at 6.9.
  • Over the past 79 months, MRSN's EV/EBIT ratio has gone up 13.2.

Below are key valuation metrics over time for MRSN.

Stock Date P/S P/B P/E EV/EBIT
MRSN 2023-12-29 6.9 5.4 -1.4 -0.7
MRSN 2023-12-28 6.9 5.4 -1.4 -0.7
MRSN 2023-12-27 6.7 5.3 -1.4 -0.6
MRSN 2023-12-26 6.4 5.0 -1.3 -0.6
MRSN 2023-12-22 6.0 4.7 -1.2 -0.5
MRSN 2023-12-21 5.7 4.5 -1.2 -0.4

MRSN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • MRSN has a Quality Grade of D, ranking ahead of 22.8% of graded US stocks.
  • MRSN's asset turnover comes in at 0 -- ranking 440th of 681 Pharmaceutical Products stocks.
  • ARNA, EYEG, and AGTC are the stocks whose asset turnover ratios are most correlated with MRSN.

The table below shows MRSN's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.000 1 -19.265
2021-03-31 0.003 1 -11.244
2020-12-31 0.003 1 -4.878
2020-09-30 0.004 1 -3.132
2020-06-30 0.011 1 -2.130
2020-03-31 0.009 1 -2.198

MRSN Price Target

For more insight on analysts targets of MRSN, see our MRSN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $26.67 Average Broker Recommendation 1.29 (Strong Buy)

Mersana Therapeutics, Inc. (MRSN) Company Bio


Mersana Therapeutics, Inc. is a biotechnology company that discovers, engineers, and develops antibody drug conjugates to cure various cancers. The company develops immune conjugate therapies to create drugs that enhance patients’ lives. It offers XMT-1522, a drug therapy for tumor models that express relatively low amounts of the HER2 protein; and human anti-HER2 antibody used in XMT-1522. Mersana Therapeutics, Inc. has strategic alliances with Takeda Pharmaceutical Company Limited; Merck Serono; and Asana BioSciences. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was founded in 2001 and is based in Cambridge, Massachusetts.


MRSN Latest News Stream


Event/Time News Detail
Loading, please wait...

MRSN Latest Social Stream


Loading social stream, please wait...

View Full MRSN Social Stream

Latest MRSN News From Around the Web

Below are the latest news stories about MERSANA THERAPEUTICS INC that investors may wish to consider to help them evaluate MRSN as an investment opportunity.

Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that on December 1, 2023, the Compensation Committee of the Board of Directors of Mersana granted an inducement award, consisting of a restricted stock unit (RSU) award to acquire 12,205 shares of its common

Yahoo | December 1, 2023

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q3 2023 Earnings Call Transcript

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q3 2023 Earnings Call Transcript November 7, 2023 Mersana Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.27, expectations were $-0.31. Operator: Good morning, and welcome to the Mersana Therapeutics Third Quarter 2023 Conference Call and Webcast. [Operator Instructions]. Please note, this call is being recorded. I would now like to […]

Yahoo | November 8, 2023

Q3 2023 Mersana Therapeutics Inc Earnings Call

Q3 2023 Mersana Therapeutics Inc Earnings Call

Yahoo | November 8, 2023

Mersana Therapeutics Inc (MRSN) Reports Q3 2023 Financial Results

Company's Q3 2023 Earnings Highlight Progress in Clinical Trials and Strategic Priorities

Yahoo | November 7, 2023

Mersana Therapeutics Provides Business Update and Announces Third Quarter 2023 Financial Results

Advancing dose escalation portion of Phase 1 clinical trial of XMT-1660, Mersana’s B7-H4 Dolasynthen ADCPreparations underway to resume enrollment in Phase 1 clinical trial of XMT-2056, Mersana’s HER2 Immunosynthen ADCCapital resources expected to support current operating plan commitments into 2026Conference call today at 8:00 a.m. ET CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering a

Yahoo | November 7, 2023

Read More 'MRSN' Stories Here

MRSN Price Returns

1-mo 20.77%
3-mo 137.74%
6-mo 212.40%
1-year -31.65%
3-year -80.16%
5-year -48.22%
YTD 62.93%
2023 -60.41%
2022 -5.79%
2021 -76.63%
2020 364.40%
2019 40.44%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!